MX2022011845A - Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2. - Google Patents

Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.

Info

Publication number
MX2022011845A
MX2022011845A MX2022011845A MX2022011845A MX2022011845A MX 2022011845 A MX2022011845 A MX 2022011845A MX 2022011845 A MX2022011845 A MX 2022011845A MX 2022011845 A MX2022011845 A MX 2022011845A MX 2022011845 A MX2022011845 A MX 2022011845A
Authority
MX
Mexico
Prior art keywords
inhibitor
bcl
combination therapy
mutant idh
mutant
Prior art date
Application number
MX2022011845A
Other languages
English (en)
Inventor
Marina Konopleva
Nathan Arthur Brooks
Raymond Gilmour
Courtney Dinardo
Vivian Salama
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2022011845A publication Critical patent/MX2022011845A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a la terapia combinada con un inhibidor de IDH mutante y un inhibidor de Bcl-2, para el tratamiento del cáncer.
MX2022011845A 2020-03-23 2021-03-22 Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2. MX2022011845A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993166P 2020-03-23 2020-03-23
US202063024743P 2020-05-14 2020-05-14
PCT/US2021/023442 WO2021194950A1 (en) 2020-03-23 2021-03-22 Combination therapy with a mutant idh inhibitor and a bcl-2 inhibitor

Publications (1)

Publication Number Publication Date
MX2022011845A true MX2022011845A (es) 2023-02-16

Family

ID=75539934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011845A MX2022011845A (es) 2020-03-23 2021-03-22 Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.

Country Status (11)

Country Link
US (1) US20230135992A1 (es)
EP (1) EP4125917B1 (es)
JP (1) JP2023520338A (es)
KR (1) KR20220156593A (es)
CN (1) CN115443137B (es)
AU (1) AU2021241470B2 (es)
BR (1) BR112022017466A2 (es)
CA (1) CA3172663A1 (es)
IL (1) IL296141A (es)
MX (1) MX2022011845A (es)
WO (1) WO2021194950A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3224704A1 (en) 2021-08-13 2023-02-16 David Andrew Coates Solid forms of 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2-enoylpiper azin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h- pyrimido[4,5-d] [1,3]oxazin-2-one
WO2023141087A1 (en) * 2022-01-19 2023-07-27 Eli Lilly And Company Combination therapy with a mutant idh inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ754115A (en) 2016-12-16 2021-07-30 Lilly Co Eli 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

Also Published As

Publication number Publication date
US20230135992A1 (en) 2023-05-04
AU2021241470A1 (en) 2022-09-29
JP2023520338A (ja) 2023-05-17
KR20220156593A (ko) 2022-11-25
EP4125917A1 (en) 2023-02-08
AU2021241470B2 (en) 2023-12-14
IL296141A (en) 2022-11-01
EP4125917B1 (en) 2024-04-17
WO2021194950A1 (en) 2021-09-30
CN115443137A (zh) 2022-12-06
BR112022017466A2 (pt) 2022-10-18
CN115443137B (zh) 2024-05-31
CA3172663A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2022000711A (es) Inhibidores de parp1.
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
PH12018502355A1 (en) Enzyme inhibitors
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
AU2019310335A8 (en) Methods of treating cancer with PI3K inhibitor, GDC-0077
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2021002805A (es) Terapias de combinacion.
MX2022000310A (es) Inhibidores de proteina bcl-2.
MX2022001933A (es) Inhibidores de enzimas.
MX2022000811A (es) Inhibidores de enzimas.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2021007484A (es) Compuestos nuevos y su uso en terapia.
MX2022002069A (es) Inhibidores de enzimas.
MX2022007626A (es) Combinaciones.
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
MX2022000545A (es) Inhibidores de enzimas.
MX2021012705A (es) Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2022011844A (es) Terapia combinada con un inhibidor de idh mutante.
MX2021015403A (es) Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario.
MX2021010603A (es) Inhibidores de caspasa y metodos de uso de los mismos.
MX2018000135A (es) Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).